Dave: My point is just that your other investment has

New Post Public Reply Private Reply Replies (2) Message Board
Churbz83 Daveludlow #16952
Dave: My point is just that your other investment has nothing to do with this one. I am also not impatient with this investment as I plan on holding a majority of my shares for many years, especially those in my ROTH. However, I am upset and it has nothing to do with the science or long term potential of the products in our portfolio. I believe it is an extremely robust portfolio with several potential therapeutics and diagnostics that could constitute being a publicly traded company of their own. But I believe Geralds tongue and habit of setting high expectations has put us in a position where only extreme milestones will move the PPS which is unfortunate. I think Geralds approach in regards to Lympro has hurt the stock price tremendously which again is unfortunate because it is probably the least valuable asset we have IMO. Everyone on this board is hoping a for a 5,10 bagger or much more. I believe due to Lympro the opportunity to see a 5 to 10 bagger pre split has dwindled tremendously if not vanished completely. I think a major order with BP and/or a elto partner/grant is the only chance we have at .20 with current structure which I think is disappointing. It says a lot when prestigious publications, orphan designations, and even first orders cant move the PPS (they should). Anyone, who feels that Gerald has not hurt the stock through (unnecessary) tweets etc is just blind. Please stop referring to my patience, if the stock hit 1 dollar tomorrow I would probably sell 5% of my holdings. My frustration is stemmed from the fact that milestones do not add value to my investment and I believe the CEO has played a major role in this. This stock is undervalued, extremely undervalued however I believe us longs will suffer a much more massive RS than might of been necessary. I expect a 50:1 split, so for an investor who were to buy in today yes I believe a 5 bagger is years away. So again GREAT COMPANY, GREAT PIPELINE, MASSIVE POTENTIAL IN TX/DX SPACE. However, too many shares and most probably substantial very near term dilution. If I were on the sidelines just learning I would probably wait to invest.

Amarantus Bioscience Holdings (AMBS) Stock Research Links

AMBS Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Angel Oak Mortgage Trust 2025-1 Receives Preliminary Ratings

Updated Category News Views 195

Angel Oak Mortgage Trust 2025-1 Ratings Overview KBRA has recently assigned preliminary ratings to various classes of mortgage-backed certificates associated with Angel Oak Mortgage Trust 2025-1 (AOMT 2025-1). This substantial transaction amounts to $342.0 million and comprises non-prime residential mortgage-backed securities (RMBS). It encompasses a pool of 631...

Continue Reading
Eagle Bancorp Montana Reports Positive Q3 Performance Growth

Updated Category News Views 177

Eagle Bancorp Montana's Strong Q3 Earnings Report Eagle Bancorp Montana, Inc. (NASDAQ: EBMT), the parent entity of Opportunity Bank of Montana, recently shared its financial results for the latest quarter. With net income reaching $2.7 million, or $0.34 per diluted share, this marks an upward trend from the previous quarter’s income of $1.7 million, equivalent to $0.22...

Continue Reading
Consumer Resilience Fuels Bank of America Amidst Slowing Trends

Updated Category News Views 310

Bank of America's Performance Overview Bank of America (NYSE: BAC) has reported a mixed performance in recent times, showing resilience in its earnings even as some sectors experience challenges. The bank's stock opened slightly higher, reflecting a cautious optimism in the market with shares trading around $46.50. For the quarter, Bank of America generated $26.6 billion...

Continue Reading
The Setai St. Maarten: A New Era in Caribbean Luxury

Updated Category News Views 136

The Setai St. Maarten: A Feast for the Senses In a stunning location along the coast, The Setai St. Maarten emerges as a jewel of luxury, introducing a captivating blend of elegance and tranquility to the Caribbean. This exciting new resort is poised to redefine the standards of Caribbean hospitality, creating unforgettable experiences for guests in a picturesque coastal...

Continue Reading
Cullinan Therapeutics Gears Up for Major Healthcare Events

Updated Category News Views 142

Cullinan Therapeutics Hosts Exciting Events at Major Conferences CAMBRIDGE, Mass. — Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a prominent biopharmaceutical firm, is set to engage the investment community with notable events at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting and the Jefferies 2025 Global Healthcare Conference. These gatherings...

Continue Reading